Matches in Nanopublications for { ?s ?p "[PAR-2 may therefore be involved in the pathophysiology of CRS and NP at different sites of activation, namely (i) proteases, (ii) the PAR-2 receptor itself or (iii) the application of novel agents that block NF-kappaB/IkappaB-alpha signalling.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 9 of
9
with 100 items per page.
- NP390371.RAU3zA3rrzxZGj7FN1v3cit22wSHO7XVrsTga997x-Ozw130_assertion description "[PAR-2 may therefore be involved in the pathophysiology of CRS and NP at different sites of activation, namely (i) proteases, (ii) the PAR-2 receptor itself or (iii) the application of novel agents that block NF-kappaB/IkappaB-alpha signalling.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP390371.RAU3zA3rrzxZGj7FN1v3cit22wSHO7XVrsTga997x-Ozw130_provenance.
- assertion description "[PAR-2 may therefore be involved in the pathophysiology of CRS and NP at different sites of activation, namely (i) proteases, (ii) the PAR-2 receptor itself or (iii) the application of novel agents that block NF-kappaB/IkappaB-alpha signalling.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP616103.RAdF03poycQpPP34b6jb1OLIRHtzqyDt7IfJoRJ2ttYlI130_assertion description "[PAR-2 may therefore be involved in the pathophysiology of CRS and NP at different sites of activation, namely (i) proteases, (ii) the PAR-2 receptor itself or (iii) the application of novel agents that block NF-kappaB/IkappaB-alpha signalling.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP616103.RAdF03poycQpPP34b6jb1OLIRHtzqyDt7IfJoRJ2ttYlI130_provenance.
- assertion description "[PAR-2 may therefore be involved in the pathophysiology of CRS and NP at different sites of activation, namely (i) proteases, (ii) the PAR-2 receptor itself or (iii) the application of novel agents that block NF-kappaB/IkappaB-alpha signalling.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[PAR-2 may therefore be involved in the pathophysiology of CRS and NP at different sites of activation, namely (i) proteases, (ii) the PAR-2 receptor itself or (iii) the application of novel agents that block NF-kappaB/IkappaB-alpha signalling.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP916223.RAiHf1eZfd3fhE7j-4kqd09g513SKMgDH6fOttDeQQ7Qw130_assertion description "[PAR-2 may therefore be involved in the pathophysiology of CRS and NP at different sites of activation, namely (i) proteases, (ii) the PAR-2 receptor itself or (iii) the application of novel agents that block NF-kappaB/IkappaB-alpha signalling.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP916223.RAiHf1eZfd3fhE7j-4kqd09g513SKMgDH6fOttDeQQ7Qw130_provenance.
- NP808783.RAvkSvPOSxem7AFw_zghOtXMBcmIZXBsW2gLJZwaUkOFY130_assertion description "[PAR-2 may therefore be involved in the pathophysiology of CRS and NP at different sites of activation, namely (i) proteases, (ii) the PAR-2 receptor itself or (iii) the application of novel agents that block NF-kappaB/IkappaB-alpha signalling.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP808783.RAvkSvPOSxem7AFw_zghOtXMBcmIZXBsW2gLJZwaUkOFY130_provenance.
- NP616098.RAjV77J6n0jjX6psAHHgr9Ox4pmNh6npshXibp41nen8o130_assertion description "[PAR-2 may therefore be involved in the pathophysiology of CRS and NP at different sites of activation, namely (i) proteases, (ii) the PAR-2 receptor itself or (iii) the application of novel agents that block NF-kappaB/IkappaB-alpha signalling.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP616098.RAjV77J6n0jjX6psAHHgr9Ox4pmNh6npshXibp41nen8o130_provenance.
- NP616101.RApEp9ZGIx4CuPSb0ePkfEfxh7riRZ7G993C_NwhlJWDo130_assertion description "[PAR-2 may therefore be involved in the pathophysiology of CRS and NP at different sites of activation, namely (i) proteases, (ii) the PAR-2 receptor itself or (iii) the application of novel agents that block NF-kappaB/IkappaB-alpha signalling.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP616101.RApEp9ZGIx4CuPSb0ePkfEfxh7riRZ7G993C_NwhlJWDo130_provenance.